HeartBeam is a pre-commercial medical technology company developing a portable, cable-free device that captures and synthesizes a clinical-grade 12-lead ECG outside of a clinical setting. The core product, the HeartBeam System, consists of a credit card-sized device, a smartphone app, a cloud-based signal processing platform, and a physician web portal. Patients press the device against their chest to capture 3D cardiac electrical signals, which HeartBeam's proprietary algorithm synthesizes into a standard 12-lead ECG — the same format used in clinical settings. Symptomatic recordings trigger an on-demand review by a board-certified cardiologist through a partnership with HeartNexus, while routine recordings are assessed by an automated arrhythmia algorithm via AccurKardia. HeartBeam received two FDA clearances (December 2024 and December 2025) covering the hardware and 12-lead synthesis software for arrhythmia assessment, and began a limited commercial launch in early 2026. The device is sold on a direct patient-pay subscription model, priced at roughly $500–$1,000 per year, bundling the device and a set number of cardiologist reads. HeartBeam's initial target customers are concierge medicine and preventive cardiology practices in Southern California and South Florida, with planned expansion into additional U.S. geographies and national concierge chains. Longer-term, HeartBeam is pursuing FDA clearance for ischemia and heart attack detection, a 12-lead ECG patch monitor, smartwatch integration, and AI-driven cardiac diagnostics built on longitudinal patient data. HeartBeam holds 25 issued patents worldwide covering its core technology.